Company profile
SOLIGENIX, INC.
NASDAQ:SNGXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DUSQUETIDE | phase3 | — | 3 | no active trials |
| HYPERICIN | phase3 | — | 5 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02013050 | phase2 | completed | 2013-12-01 | 2015-12-01 | Soligenix | A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer |
| NCT01073384 | phase1_2 | completed | 2009-12-01 | 2012-01-01 | Soligenix | A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer |
| NCT06470451 | phase3 | terminated | 2025-01-07 | 2026-05-22 | Soligenix | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL |
| NCT03237325 | phase3 | completed | 2017-12-04 | 2020-06-24 | Soligenix | DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer |
| NCT06386744 | phase2 | completed | 2024-11-18 | 2025-05-23 | Soligenix | Dusquetide for the Treatment of Behcet's Disease |
FDA applications (0)
No records yet.